间充质干细胞治疗的生物安全研究进展

Research progress on the biosafety of mesenchymal stem cells

间充质干细胞是一群自我复制能力强、具有高度分化潜能的细胞,来源广泛,是细胞治疗的首要来源。在组织修复、自身免疫疾病和退行性疾病治疗中具有较高的价值。生物安全是间充质干细胞临床转化的主要障碍之一,但目前缺乏足够的认识,本文从间充质干细胞的遗传稳定性、致肿瘤发生、免疫原性方面阐述间充质干细胞的生物安全研究进展,以期提高间充质干细胞治疗的生物安全意识,为其间充质干细胞安全评价和临床转化提供参考。

Mesenchymal stem cells(MSCs)possess the ability to self-renew and give rise to highly differentiated cell types,and can be isolated from a wide range of sources,making them the first choice for cell therapy.MSCs are widely used in tissue repair,autoimmune diseases and degenerative diseases,and have high value.Currently,biosafety is one of the most challenging problems in the clinical translation of MSCs.Previous research on the biosafety of MSCs has been largely unclear.Therefore,we reviewed the research progress on several aspects of MSC biosafety,including genetic stability,tumorigenicity and immunogenicity.This review may provide a reference for the safety evaluation and clinical transformation of MSCs.